These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 11330168)

  • 21. Practical steps for targeting heart disease's biggest villain.
    Clin Resour Manag; 2001 Dec; 2(12):190-1, 177. PubMed ID: 11794829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I.
    Superko HR; McGovern ME; Raul E; Garrett B
    Am J Cardiol; 2004 Sep; 94(5):588-94. PubMed ID: 15342288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A statin in every medicine cabinet?
    Walsh MN
    Health News; 2002 Sep; 8(9):3. PubMed ID: 12229899
    [No Abstract]   [Full Text] [Related]  

  • 24. [Effect of enduracin on the activity of a cholesterol ester transfer protein in blood plasma of people with hypercholesteremia].
    Gorshkova IN; Kiseleva NG; Akhmedzhanov NM; Perova NV
    Biull Eksp Biol Med; 1996 Feb; 121(2):185-7. PubMed ID: 9026127
    [No Abstract]   [Full Text] [Related]  

  • 25. Simcor: a niacin/simvastatin combination.
    Med Lett Drugs Ther; 2008 Apr; 50(1283):25-6. PubMed ID: 18391898
    [No Abstract]   [Full Text] [Related]  

  • 26. Coping with cholesterol. The waxy buildup in our blood vessels is a leading cause of fatal heart disease. Do dietary supplements add anything to the arsenal against it?
    Kalb C
    Newsweek; 2000 Jun; 135(25):73, 75. PubMed ID: 10977154
    [No Abstract]   [Full Text] [Related]  

  • 27. Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy.
    Duvall WL; Blazing MA; Saxena S; Guyton JR
    J Cardiovasc Risk; 2002 Dec; 9(6):339-47. PubMed ID: 12478203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Choice of cholesterol-lowering drugs. The Medical Letter.
    Conn Med; 1988 Nov; 52(11):671-3. PubMed ID: 3233971
    [No Abstract]   [Full Text] [Related]  

  • 29. Adipokines and treatment with niacin.
    Westphal S; Borucki K; Taneva E; Makarova R; Luley C
    Metabolism; 2006 Oct; 55(10):1283-5. PubMed ID: 16979396
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of cholesteryl ester transfer protein inhibitor on vitamin E transport should be studied.
    Masterjohn C
    Am Heart J; 2009 Jul; 158(1):e11; author reply e13. PubMed ID: 19540377
    [No Abstract]   [Full Text] [Related]  

  • 31. What about Niacin?
    Medical Letter
    Med Lett Drugs Ther; 2011 Nov; 53(1378):93-4. PubMed ID: 22113122
    [No Abstract]   [Full Text] [Related]  

  • 32. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.
    Birjmohun RS; Hutten BA; Kastelein JJ; Stroes ES
    J Am Coll Cardiol; 2005 Jan; 45(2):185-97. PubMed ID: 15653014
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of niacin-bound chromium and grape seed proanthocyanidin extract on the lipid profile of hypercholesterolemic subjects: a pilot study.
    Preuss HG; Wallerstedt D; Talpur N; Tutuncuoglu SO; Echard B; Myers A; Bui M; Bagchi D
    J Med; 2000; 31(5-6):227-46. PubMed ID: 11508317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
    Maccubbin D; Bays HE; Olsson AG; Elinoff V; Elis A; Mitchel Y; Sirah W; Betteridge A; Reyes R; Yu Q; Kuznetsova O; Sisk CM; Pasternak RC; Paolini JF
    Int J Clin Pract; 2008 Dec; 62(12):1959-70. PubMed ID: 19166443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Artery magic.
    Comarow A
    US News World Rep; 2003 Nov; 135(17):60-1. PubMed ID: 14666540
    [No Abstract]   [Full Text] [Related]  

  • 36. [Correction of hyperlipidemia with Allicor].
    Andrianova IV; Demidova OM; Medvedeva LA; Latyshev OA
    Klin Med (Mosk); 2004; 82(4):56-8. PubMed ID: 15164512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Unexpected cholesterol measurement in patients with hypercholesterolemia].
    Díaz Calleja C; Pastor Pastor J; Bellés Calvo A; Haya Guaita A
    Med Clin (Barc); 1997 Sep; 109(7):276-7. PubMed ID: 9333696
    [No Abstract]   [Full Text] [Related]  

  • 38. Niacin and lipoprotein(a): facts, uncertainties, and clinical considerations.
    Scanu AM; Bamba R
    Am J Cardiol; 2008 Apr; 101(8A):44B-47B. PubMed ID: 18375241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
    Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM
    J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A meta-analysis of randomized controlled studies on the effects of extended-release niacin in women.
    Goldberg AC
    Am J Cardiol; 2004 Jul; 94(1):121-4. PubMed ID: 15219522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.